Vexev, announced the highly successful results of the CANSCAN Trial (NCT06691672), providing evidence that the VxWave ...

The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically ...

Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading ...

Vexev and U.S. Renal Care today announced successful results from the CANSCAN trial of the VxWave robotic ultrasound imaging system.

The cost of emergency dialysis is estimated to be eight times that of in-center dialysis. A new study reveals that a ...

Venova Medical Announces First Subjects Enrolled in VENOS-3 Pivotal IDE Study of the Velocity (R) Percutaneous AVF System The Velocity System is a next generation percutaneous AVF technology designed ...

The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) ...

The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional ...

A transitional dialysis program piloted in Austin, TX lowered the use ofcostly emergency dialysis in uninsured people with kidney failure, and it facilitated permanent dialysis access placement and ...

The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional dialysis program piloted ...